시장보고서

상품코드

1339169

자궁근종 치료 시장, 점유율, 규모, 동향, 산업 분석 보고서 : 약물 유형별, 약물 유형별, 최종 용도별, 지역별, 부문별 예측(2023-2032년)

Uterine Fibroid Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Drug Type (Submucosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids); By End Use; By Region, & Segment Forecasts, 2023-2032

발행일: 2023년 07월 | 리서치사:

Polaris Market Research | 페이지 정보: 영문 118 Pages | 배송안내 : 1-2일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 연구에 따르면, 세계 자궁근종 치료 시장 규모는 2032년까지 108억 3,000만 달러에 달할 것으로 예상됩니다. 이 조사 보고서는 현재 시장 역학에 대한 자세한 통찰력과 미래 시장 성장에 대한 분석을 제공합니다.

자궁근종(UF)은 가임기 여성에게 영향을 미치는 흔한 질환으로 월경 과다 출혈이 가장 흔한 증상 중 하나이며, GnRH 길항제 및 황체호르몬 방출 IUD와 같은 새로운 약물의 개발로 인해 자궁근종 환자에게 보다 효과적인 치료 옵션이 제공되고 있습니다. 이러한 요인들은 인지도와 진단 증가와 함께 시장 성장을 가속하고 있습니다.

IntechOpen의 분석에 따르면, 월경과다 출혈은 UF의 가장 흔한 증상으로 매년 140만 명에 가까운 여성들이 겪고 있습니다. 또한, 여성의 약 60%가 신체 활동 감소 및 삶의 질 저하와 같은 증상을 호소하고 있습니다.

자궁근종에 대한 보다 효과적이고 안전한 치료법에 대한 수요가 증가하고 있으며, 이는 이 분야의 연구개발에 대한 원동력이 되고 있습니다. 연구 활동에 대한 자금 지원이 증가함에 따라 보다 진보적이고 혁신적인 치료법이 개발될 것으로 예상되며, 이는 시장 성장을 더욱 촉진할 것으로 보입니다. 또한, 개인 맞춤형 의료 및 정밀 치료의 발전은 환자 개개인에게 보다 효과적인 치료 옵션을 제공할 수 있기 때문에 시장 성장을 가속할 것으로 예상됩니다.

최근 여성건강연구협회(SWHR)가 '2021년 스테파니 터브스 존스 자궁근종 연구 및 교육법(Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021)'을 지지하고 재제안한 바 있다, 자궁근종 연구에 자금을 지원하고 지원함으로써 새로운 치료법 개발이 촉진될 것으로 기대됩니다. 또한, 최근 마이펜브리 등 여러 GnRH 길항제가 자궁근종에 따른 대량 출혈 치료제로 승인된 것도 시장 성장에 힘을 실어줄 것으로 보입니다.

자궁근종 치료 시장 보고서 하이라이트

GnRH 길항제 부문은 높은 효능과 효과적인 치료 옵션으로 인해 더 빠른 성장이 예상됩니다.

점막하 자궁근종 시장이 가장 큰 점유율을 차지하고 있습니다. 이는 주로 높은 유병률과 심각성 때문입니다. 아시아 여성에게 더 흔합니다.

약물 및 기타 병용요법을 쉽게 구할 수 있기 때문에 소매 약국 부문이 큰 점유율을 차지할 것으로 예상됩니다.

북미는 미국 내 높은 유병률, 의료시설의 확충, 개인의 피해에 대한 높은 인식 등으로 인해 더 큰 성장이 예상되고 있습니다.

주요 조사 결과
서론
- 자궁근종 치료 시장 평가, 지역별, 2019-2032년
자궁근종 치료 시장 - 북미
- 북미 : 자궁근종 치료 시장, 약제 클래스별, 2019-2032년
- 북미 : 자궁근종 치료 시장, 최종 용도별, 2019-2032년
- 북미 : 자궁근종 치료 시장, 약제 유형별, 2019-2032년
- 자궁근종 치료 시장 - 미국
- 자궁근종 치료 시장 - 캐나다
자궁근종 치료 시장 - 유럽
- 유럽 : 자궁근종 치료 시장, 약제 클래스별, 2019-2032년
- 유럽 : 자궁근종 치료 시장, 최종 용도별, 2019-2032년
- 유럽 : 자궁근종 치료 시장, 약제 유형별, 2019-2032년
- 자궁근종 치료 시장 - 영국
- 자궁근종 치료 시장 - 프랑스
- 자궁근종 치료 시장 - 독일
- 자궁근종 치료 시장 - 이탈리아
- 자궁근종 치료 시장 - 스페인
- 자궁근종 치료 시장 - 네덜란드
- 자궁근종 치료 시장 - 러시아
자궁근종 치료 시장 - 아시아태평양
- 아시아태평양 : 자궁근종 치료 시장, 약제 클래스별, 2019-2032년
- 아시아태평양 : 자궁근종 치료 시장, 최종 용도별, 2019-2032년
- 아시아태평양 : 자궁근종 치료제 시장, 약제 유형별, 2019-2032년
- 자궁근종 치료 시장 - 중국
- 자궁근종 치료 시장 - 인도
- 자궁근종 치료 시장 - 말레이시아
- 자궁근종 치료 시장 - 일본
- 자궁근종 치료 시장 - 인도네시아
- 자궁근종 치료 시장 - 한국
자궁근종 치료 시장 - 중동 및 아프리카
- 중동 및 아프리카 : 자궁근종 치료 시장, 약제 클래스별, 2019-2032년
- 중동 및 아프리카 : 자궁근종 치료 시장, 최종 용도별, 2019-2032년
- 중동 및 아프리카 : 자궁근종 치료 시장, 약제 유형별, 2019-2032년
- 자궁근종 치료 시장 - 사우디아라비아
- 자궁근종 치료 시장 - UAE
- 자궁근종 치료 시장 - 이스라엘
- 자궁근종 치료 시장 - 남아프리카
자궁근종 치료 시장 - 라틴아메리카
- 라틴아메리카 : 자궁근종 치료 시장, 약제 클래스별, 2019-2032년
- 라틴아메리카 : 자궁근종 치료 시장, 최종 용도별, 2019-2032
- 라틴아메리카 : 자궁근종 치료 시장, 약제 유형별, 2019-2032년
- 자궁근종 치료 시장 - 멕시코
- 자궁근종 치료 시장 - 브라질
- 자궁근종 치료 시장 - 아르헨티나

제9장 경쟁 구도

확장 및 인수 분석
- 확장
- 인수
제휴/협업/합의/공개

제10장 기업 개요

Myovant Sciences
Pfizer
Abbvie
Ferring
AstraZeneca
Bayer
Amring Pharmaceuticals
Watson Pharma

LSH 23.10.19

The global uterine fibroid treatment market size is expected to reach USD 10.83 billion by 2032, according to a new study by Polaris Market Research. The report "Uterine Fibroid Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Drug Type (Submucosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids); By End Use; By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Uterine fibroids (UF) are a common condition affecting women of reproductive age, with heavy menstrual bleeding being one of the most common symptoms. The development of novel drugs, such as GnRH antagonists and progestin-releasing IUDs, has provided more effective treatment options for women with uterine fibroids. These factors, along with increased awareness and diagnosis, are driving the growth of the market.

As per the analysis done by the IntechOpen, excessive menstrual bleeding is the most common symptom in the UF, affecting almost 1.4 Mn women each year. Moreover, around 60 percent of the women have reported the symptoms of physical in-activity and quality of life.

Demand for more effective and safer treatment options for uterine fibroids is increasing, and this is driving research and development efforts in the field. With increased funding for research activities, the development of more advanced and innovative treatment options is expected, which will further drive the growth of the market. Additionally, the development of personalized medicine and precision therapies is also expected to drive growth in the market, as these approaches may offer more targeted and effective treatment options for individual patients.

The recent endorsement and reintroduction of the Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021 by the Society for Women's Health Research (SWHR) will provide funding and support for research on uterine fibroids, which is expected to boost the development of novel treatments. Additionally, the recent approval of multiple GnRH antagonists such as Myfembree for the treatment of heavy bleeding associated with fibroids will also drive the market growth.

Uterine Fibroids Treatment Market Report Highlights

GnRH antagonists' segment is anticipated to witness faster growth owing to its high efficacy and effective treatment option.

Sub-mucosal fibroids segment accounted for the larger market share. This is primarily due its high prevalence rate and severity. It is most common among Asian women

Retail pharmacies segment expected to garner substantial share, owing to easy availability of drugs and other combination therapies

North America is expected to grow larger revenue, owing to high prevalence rate in the US. presence of better medical facilities, and awareness among individuals about ill effects.

The global players include: Myovant Sciences, Pfizer, Abbvie, Ferring, AstraZeneca, Bayer, Amring Pharmaceuticals, and Watson Pharma.

Polaris Market Research has segmented the uterine fibroids treatment market report based on drug type, drug class, end use, and region:

Uterine Fibroids Treatment, Drug Type Outlook (Revenue - USD Billion, 2019 - 2032)

Subserosal Fibroids
Intramural Fibroids
Submucosal Fibroids
Pedunculated Fibroids

Uterine Fibroids Treatment, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

Gonadotropin-releasing Hormone (GnRH) Agonists
Gonadotropin-releasing Hormone (GnRH) Antagonists
Progestin-releasing Intrauterine Device (IUD) & Contraceptives
Non-hormonal Medications
Others

Uterine Fibroids Treatment, End Use Outlook (Revenue - USD Billion, 2019 - 2032)

Hospital Pharmacies
Retail Pharmacies
Others

Uterine Fibroids Treatment, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Latin America
Argentina
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data End Uses
- 3.2.1. Primary End Uses
- 3.2.2. Secondary End Uses

4. Global Uterine Fibroid Treatment Market Insights

4.1. Uterine Fibroid Treatment Market - End Use Snapshot
4.2. Uterine Fibroid Treatment Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Increasing Population Base For Uterine Fibroids Patients
  - 4.2.1.2. Growing Awareness Initiatives Related To Uterine Fibroids Diagnosis And Treatment
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. Stringent Regulatory Framework
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Uterine Fibroid Treatment Market End Use Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Uterine Fibroid Treatment Market, by Drug Class

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
5.3. Gonadotropin-releasing Hormone (GnRH) Agonists
- 5.3.1. Global Uterine Fibroid Treatment Market, by Gonadotropin-releasing Hormone (GnRH) Agonists, by Region, 2019-2032 (USD Billion)
5.4. Gonadotropin-releasing Hormone (GnRH) Antagonists
- 5.4.1. Global Uterine Fibroid Treatment Market, by Gonadotropin-releasing Hormone (GnRH) Antagonists, by Region, 2019-2032 (USD Billion)
5.5. Progestin-releasing Intrauterine Device (IUD) & Contraceptives
- 5.5.1. Global Uterine Fibroid Treatment Market, by Progestin-releasing Intrauterine Device (IUD) & Contraceptives, by Region, 2019-2032 (USD Billion)
5.6. Non-hormonal Medications
- 5.6.1. Global Uterine Fibroid Treatment Market, by Non-hormonal Medications, by Region, 2019-2032 (USD Billion)
5.7. Others
- 5.7.1. Global Uterine Fibroid Treatment Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Uterine Fibroid Treatment Market, by Drug Type

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
6.3. Subserosal Fibroids
- 6.3.1. Global Uterine Fibroid Treatment Market, by Subserosal Fibroids, by Region, 2019-2032 (USD Billion)
6.4. Intramural Fibroids
- 6.4.1. Global Uterine Fibroid Treatment Market, by Intramural Fibroids, by Region, 2019-2032 (USD Billion)
6.5. Submucosal Fibroids
- 6.5.1. Global Uterine Fibroid Treatment Market, by Submucosal Fibroids, by Region, 2019-2032 (USD Billion)
6.6. Pedunculated Fibroids
- 6.6.1. Global Uterine Fibroid Treatment Market, by Pedunculated Fibroids, by Region, 2019-2032 (USD Billion)

7. Global Uterine Fibroid Treatment Market, by End Use

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
7.3. Hospital Pharmacies
- 7.3.1. Global Uterine Fibroid Treatment Market, by Hospital Pharmacies, By Region, 2019-2032 (USD Billion)
7.4. Retail Pharmacies
- 7.4.1. Global Uterine Fibroid Treatment Market, by Retail Pharmacies, By Region, 2019-2032 (USD Billion)
7.5. Others
- 7.5.1. Global Uterine Fibroid Treatment Market, by Others, By Region, 2019-2032 (USD Billion)

8. Global Uterine Fibroid Treatment Market, by Geography

8.1. Key findings
8.2. Introduction
- 8.2.1. Uterine Fibroid Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
8.3. Uterine Fibroid Treatment Market - North America
- 8.3.1. North America: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 8.3.2. North America: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
- 8.3.3. North America: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
- 8.3.4. Uterine Fibroid Treatment Market - U.S.
  - 8.3.4.1. U.S.: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 8.3.4.2. U.S.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  - 8.3.4.3. U.S.: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
- 8.3.5. Uterine Fibroid Treatment Market - Canada
  - 8.3.5.1. Canada: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 8.3.5.2. Canada.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  - 8.3.5.3. Canada: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.4. Uterine Fibroid Treatment Market - Europe
- 8.4.1. Europe: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 8.4.2. Europe.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
- 8.4.3. Europe: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
- 8.4.4. Uterine Fibroid Treatment Market - UK
  - 8.4.4.1. UK: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 8.4.4.2. UK.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  - 8.4.4.3. UK: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
- 8.4.5. Uterine Fibroid Treatment Market - France
  - 8.4.5.1. France: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 8.4.5.2. France.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  - 8.4.5.3. France: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
- 8.4.6. Uterine Fibroid Treatment Market - Germany
  - 8.4.6.1. Germany: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 8.4.6.2. Germany.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  - 8.4.6.3. Germany: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
- 8.4.7. Uterine Fibroid Treatment Market - Italy
  - 8.4.7.1. Italy: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 8.4.7.2. Italy.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  - 8.4.7.3. Italy: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
- 8.4.8. Uterine Fibroid Treatment Market - Spain
  - 8.4.8.1. Spain: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 8.4.8.2. Spain.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  - 8.4.8.3. Spain: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
- 8.4.9. Uterine Fibroid Treatment Market - Netherlands
  - 8.4.9.1. Netherlands: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 8.4.9.2. Netherlands.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  - 8.4.9.3. Netherlands: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
- 8.4.10. Uterine Fibroid Treatment Market - Russia
  - 8.4.10.1. Russia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 8.4.10.2. Russia.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  - 8.4.10.3. Russia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.5. Uterine Fibroid Treatment Market - Asia Pacific
- 8.5.1. Asia Pacific: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 8.5.2. Asia Pacific.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
- 8.5.3. Asia Pacific: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
- 8.5.4. Uterine Fibroid Treatment Market - China
  - 8.5.4.1. China: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 8.5.4.2. China.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  - 8.5.4.3. China: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
- 8.5.5. Uterine Fibroid Treatment Market - India
  - 8.5.5.1. India: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 8.5.5.2. India.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  - 8.5.5.3. India: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
- 8.5.6. Uterine Fibroid Treatment Market - Malaysia
  - 8.5.6.1. Malaysia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 8.5.6.2. Malaysia.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  - 8.5.6.3. Malaysia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
- 8.5.7. Uterine Fibroid Treatment Market - Japan
  - 8.5.7.1. Japan: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 8.5.7.2. Japan.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  - 8.5.7.3. Japan: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
- 8.5.8. Uterine Fibroid Treatment Market - Indonesia
  - 8.5.8.1. Indonesia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 8.5.8.2. Indonesia.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  - 8.5.8.3. Indonesia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
- 8.5.9. Uterine Fibroid Treatment Market - South Korea
  - 8.5.9.1. South Korea: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 8.5.9.2. South Korea.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  - 8.5.9.3. South Korea: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.6. Uterine Fibroid Treatment Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 8.6.2. Middle East & Africa.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
- 8.6.3. Middle East & Africa: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
- 8.6.4. Uterine Fibroid Treatment Market - Saudi Arabia
  - 8.6.4.1. Saudi Arabia: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 8.6.4.2. Saudi Arabia.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  - 8.6.4.3. Saudi Arabia: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
- 8.6.5. Uterine Fibroid Treatment Market - UAE
  - 8.6.5.1. UAE: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 8.6.5.2. UAE.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  - 8.6.5.3. UAE: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
- 8.6.6. Uterine Fibroid Treatment Market - Israel
  - 8.6.6.1. Israel: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 8.6.6.2. Israel.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  - 8.6.6.3. Israel: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
- 8.6.7. Uterine Fibroid Treatment Market - South Africa
  - 8.6.7.1. South Africa: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 8.6.7.2. South Africa.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  - 8.6.7.3. South Africa: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
8.7. Uterine Fibroid Treatment Market - Latin America
- 8.7.1. Latin America: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
- 8.7.2. Latin America.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
- 8.7.3. Latin America: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
- 8.7.4. Uterine Fibroid Treatment Market - Mexico
  - 8.7.4.1. Mexico: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 8.7.4.2. Mexico.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  - 8.7.4.3. Mexico: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
- 8.7.5. Uterine Fibroid Treatment Market - Brazil
  - 8.7.5.1. Brazil: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 8.7.5.2. Brazil.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  - 8.7.5.3. Brazil: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)
- 8.7.6. Uterine Fibroid Treatment Market - Argentina
  - 8.7.6.1. Argentina: Uterine Fibroid Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  - 8.7.6.2. Argentina.: Uterine Fibroid Treatment Market, by End Use, 2019-2032 (USD Billion)
  - 8.7.6.3. Argentina: Uterine Fibroid Treatment Market, by Drug Type, 2019-2032 (USD Billion)

9. Competitive Landscape

9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

10.1. Myovant Sciences
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Drug Class Benchmarking
- 10.1.4. Recent Development
10.2. Pfizer
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Drug Class Benchmarking
- 10.2.4. Recent Development
10.3. Abbvie
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Drug Class Benchmarking
- 10.3.4. Recent Development
10.4. Ferring
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Drug Class Benchmarking
- 10.4.4. Recent Development
10.5. AstraZeneca
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Drug Class Benchmarking
- 10.5.4. Recent Development
10.6. Bayer
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Drug Class Benchmarking
- 10.6.4. Recent Development
10.7. Amring Pharmaceuticals
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Drug Class Benchmarking
- 10.7.4. Recent Development
10.8. Watson Pharma
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Drug Class Benchmarking
- 10.8.4. Recent Development

자궁근종 치료 시장, 점유율, 규모, 동향, 산업 분석 보고서 : 약물 유형별, 약물 유형별, 최종 용도별, 지역별, 부문별 예측(2023-2032년)

Uterine Fibroid Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Drug Type (Submucosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids); By End Use; By Region, & Segment Forecasts, 2023-2032

자궁근종 치료 시장 보고서 하이라이트

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 세계의 자궁근종 치료 시장에 관한 인사이트

제5장 세계의 자궁근종 치료 시장, 약제 클래스별

제6장 세계의 자궁근종 치료 시장, 약제 유형별

제7장 세계의 자궁근종 치료 시장, 최종 용도별

제8장 세계의 자궁근종 치료 시장, 지역별